Summary: Kinetics of L-3,4-dihydroxy-6-[18Fjfluoro phenylalanine (FDOP A) in striatum and cerebellum were measured in 10 normal human subjects with positron emission tomography (PET) from 0 to 120 min after an intravenous bolus injection of the tracer. The time course of the arterial plasma concentrations of the tracer and its metabolites was also assayed biochemically. FDOP A compartmental models that are based on biochemical in formation were investigated for their consistency with the measured striatal and cerebellar tissue kinetics. A mod eling approach was also developed for separating plasma FDOP A and metabolite time-activity curves from the measured total 18F time-activity curve in plasma. Results showed that a model consisting of three separate com partments for tissue FDOPA, tissue 6-[18FJfluorodopa mine (FDA) and its metabolites , and tissue L-3,4-di hydrox y -6-[18Fjfl uoro-3-O-meth y I phen ylalanine (3-OMFD) could describe adequately the striatal kinetics in humans. Based on this model , the FDOPA transport con stant across the blood-brain barrier (BBB) (K 1 ), the L-3 ,4-Dihydroxy-6-[ 18 F]fluorophenylalanine (FDOPA) has been widely used with positron emis sion tomography (PET) to examine changes in the presynaptic dopaminergic function in animals and humans (Garnett et al., 1983a (Garnett et al., , 1984 CaIne et al., Received December 12, 1990; revised May 6, 1991; accepted May 10, 1991. Address correspondence and reprint requests to Dr. S.-C. Huang at Division of Nuclear Medicine, Department of Radio logical Sciences, UCLA School of Medicine, 405 Hilgard Ave., Los Angeles, CA 90024, U.S.A.
FDOPA decarboxylation rate constant (k3)' and the turn over rate constant of FDA and its metabolites (k4) could be estimated by model fitting to the tissue kinetics and were found for the normal subjects to be 0.031 ± 0.006 mlimin/g (mean ± SD), 0.041 ± 0.015/min , and 0.004 ± 0.002/min , respectively. About 50% of the FDOPA that crossed the BBB from plasma to striatum was decarbox ylated. The decarboxylation constant with respect to plasma FDOPA (K3) was 0.015 ± 0.003 mlimin/g. The BBB transport corresponded to a permeability-surface area product of 0.032 mlimin/g for FDOPA. For 3-0MFD , the BBB transport was 1.7 times faster. The effects of tissue heterogeneity on the FDOP A kinetics and on the estimated model parameters were also investigated. The usefulness and implications of these findings for interpre tation of PET FDOPA studies are discussed. Key Words: Blood-brain transport-Blood time-activity curve Cerebellum-L-3 ,4-Dihydroxy-6-[ 18Fjfluorophenylala nine-L-3 ,4-Dihydroxy-6-[18Fjfluoro-3-0-methylphenyla lanine turnover rate-Striatum.
1985; Nahmias et al ., 1985; Chiueh et al., 1986; Fir nau et al ., 1986; Martin et al., 1986 Martin et al., , 1989 Guttman et al., 1987 Guttman et al., , 1989 Leenders et al., 1987 Leenders et al., , 1988 Freed et al., 1990; Lindvall et al ., 1990) . In normal sub jects, the tracer is converted to 6-e 8 F]fluorodopa mine (FDA) by aromatic amino acid decarboxylase (AAAD) and retained in the striatum . FDOPA up take is decreased in patients with Parkinson's dis ease or with N-methyl-4-phenyl-l ,2,3,6-tetrahydro pyridine-induced degeneration of the nigrostriatal pathway . Therefore, the uptake of the tracer in the striatal region has been useful for indicating the pre synaptic integrity of dopaminergic neurons (Barrio et al., 1988) . The interpretation of the results, how ever, has been mostly by qualitative examination of the relative radioactivity distribution in the brain (Garnett et al., 1983a (Garnett et al., ,b, 1984 Caine et al., 1985; Guttman et al., 1989) . One important feature of FDOPA kinetics is that the tracer is rapidly con verted systemically to L-3,4-dihydroxy-6-[ 18 F]fluoro-3-0-methylphenylalanine (3-0MFD) (Boyes et al., 1986; Cumming et al., 1987; Firnau et al., 1987; Melega et al., 1990a ) that in turn can cross the blood-brain barrier (BBB) and contribute to the total radioactivity measured in cerebral tissue . This complicates the interpretation of PET images, in which only the total radioactivity concentration in local tissue regions can be measured .
Early quantitative studies have used the radioac tivity ratio between striatum and cerebellum (or background) at 60-120 min after FDOPA injection as an index to differentiate between normals and patients (CaIne et al ., 1985; Leenders et al., 1986a; Martin et al., 1986; Doudet et al., 1989) . In some studies, the background activity level (cerebellum) has been subtracted from the striatal activity before taking the ratio to minimize the effect of 3-0MFD in tissue (Guttman et al., 1989) . The striatum/ cerebellum ratio of 18 F concentration has been shown to increase approximately at a constant rate after the time of injection (Leenders et al., 1986b) . Modeling analysis has been applied to show that plots of this ratio versus the normalized time (Patlak et al., 1983) , using either the cerebellar time-activity curve or the total blood activity curve as the input function, are approximately linear (Leenders et al., 1989; Lindvall et al ., 1990; Tedroff et al., 1990) . The Patlak graphical method has also been formally ap plied to analyze FDOPA data using the plasma FDOPA curve as the input func tion to give the uptake constant of FDOPA from plasma to striatum . In contrast to earlier analyses, this last approach explicitly accounted for 3-0MFD in plasma and in tissue.
The uptake constant of FDOPA obtained by this approach, however, is not specific to the AAAD activity in striatal tissue, because the uptake could be affected directly by changes in the transport mechanism across the BBB . Also, although a gen eral model based on the biochemical pathways of FDOPA has been used in the last two methods re viewed above, the model has not been fully inves tigated for its adequacies and limitations in describ ing FDOPA kinetics in the striatum.
A well-characterized model for the kinetics of FDOPA can enhance our understanding of the PET measurements and in turn can lead to the develop ment of more reliable techniques for analyzing and interpreting results from FDOPA studies (Huang et al., 1989; Yu et al., 1990 ). An FDOPA model had been examined previously (Garnett et al., 1980) , but with kinetic data obtained from monkey studies in which an external scintillation detector was used. These measurements were more representative of the kinetics in the extracerebral and nonstriatal ce rebral tissues than of striatal tissues. The results, therefore, have not been utilized for the analysis of FDOPA PET data. Recently, an FDOPA model based on known biochemical information about the tracer has been used for analyzing FDOPA kinetics in rat . The model, however, has not been directly verified in terms of its adequacy to describe the kinetics of FDOPA in cerebral tissue.
In this study, we perform dynamic PET studies of FDOPA in normal human subjects to assess human striatal FDOPA kinetics. We investigate the model configuration that best describes these kinetics and is consistent with quantitative biochemical informa tion known for this tracer (Melega et al. 199 1a, b) . This model demonstrates the feasibility of measur ing the turnover rate constant of FDA and its me tabolites in tissue with PET. A new approach to separate the time-activity curves of FDOPA and its labeled metabolites is also introduced. The charac teristics of the model in terms of the reliability of the estimate of the model parameters are presented. Figure 1 illustrates the various transport and bio chemical pathways of FDOPA in the human body. The tracer is assumed to have access to bidirec tional transport across the BBB . The transport mechanism is the neutral amino acid carrier in the BBB (Oldendorf, 1971) . In striatum, FDOPA is de carboxylated to FDA by AAAD in presynaptic do paminergic terminals. Similar to dopamine, FDA will be released from these neurons into the synap tic cleft and can be transported back into neurons' reuptake sites . FDA can also be metabolized to 6-[ 18 F]fluoro-3 ,4-dihydroxyphenylacetic acid (FDOPAC) and 6-[ 18 F]fluorohomovanillic acid (FHVA), which in turn can cross the BBB and be cleared from tissue by venous blood flow. Plasma FDOPA is also converted to 3-0MFD in the periph ery, such as the liver, kidney, and the red blood cell, and appears rapidly in plasma (Cumming et al., 1987; Firnau et al., 1987; Melega et al., 1990a) . 3-0MFD can cross the BBB through the neutral amino acid carrier as does FDOPA, but probably with a different permeability. 3-0MFD of periph eral origin is assumed not to participate in any bio chemical reactions in brain tissues and the rate of direct conversion from FDOPA to 3-0MFD in stri atum is assumed small and negligible. Similar trans- port properties are assumed for FDOPA and 3-0MFD in cerebellum, except that FDOPA is not converted to FDA as determined by biochemical assay of cerebellar tissue (Melega et aI ., 1991a.b) .
THEORY

Models for FDOP A in striatum and cerebellum
Based on the above information, compartmental models for the tracer in striatum and cerebellum can be configured as shown in Fig. 2A and B. For stri atum, the model consists of separate compartments for tissue FDOPA, tissue 3-0MFD, and FDA (and its metabolites). The IS F radioactivity concentra tions in the three compartments are denoted, re spectively, as Cl, C2, and C3; K[ and k2 are the forward and reverse transport rate constants of plasma FDOPA to the tissue FDOPA compartment; k3 is the rate constant from the tissue FDOPA com partment to the combined compartment of FDA and its metabolites; k4 is the clearance rate constant of IS F out of the tissue to plasma from the compart ment of FDA and its metabolites; K5 and k6 are, respectively, the forward and reverse transport rate constants of plasma 3-0MFD to the tissue 3-0MFD compartment. According to this model, the striatal [S F concentration [Cs(t) ] at time t can be expressed as
where Cfd and Cornfd are, respectively, the radioac tivity concentrations of FDOPA and 3-0MFD in plasma; Cwb(t) is the [S F concentration in whole blood; CBV denotes the blood volume in tissue; and the symbol * denotes the mathematical operation of convolution . The time average striatal radioactivity (Csm) corresponding to a PET measurement over a scan interval from t [ to t2 can then be expressed as (2) As shown in Fig. 2B , the model for cerebellum is similar to that for striatum, except that there is no compartment for FDA and that k3 is zero . A sub script "p" is added to each notation for the cere bellar model to distinguish them from those of the striatal model. The total IS F concentration in cere bellum [Cc(t)] can then be expressed as 
Similarly, the time average cerebellar radioactivity corresponding to a PET scan from time tl to t2 is (4)
Model for plasma FDOP A and 3-0MFD
Since plasma 3-0MFD is a product of plasma FDOPA, the relationship between the two concen trations can be described by the compartment shown in Fig. 2C . In this model, kbl is the unidirec tional transfer rate constant from plasma FDOPA to the plasma 3-0MFD compartment. The extravascu lar 3-0MFD compartment communicates bidirec tionally with the plasma 3-0MFD compartment with rate constants kb2 and kb3 as shown in the fig ure. The total radioactivities in the plasma and ex travascular 3-0MFD compartments are denoted as Qb2 and Qb3 ' respectively. The volumes of the two compartments are Vb2 and Vb3. Based on this model, the kinetics of plasma FDOPA and 3-0MFD concentrations are related by the following differ ential equation:
Note that Comfd = Qb2/Vb2' and by adding and sub tracting kblComfd ( = kb1Qb2/Vb2) on the right-hand side of the first equation, one can obtain
where (Cfd + C O m f d) is the total 1 8 F concentration in plasma (C n 8 ). By dividing both equations by Vb2 (on both sides), the above equation can be expressed (Huang et aI., 1991) as
where kbl2 = kb/Vb2 and Cx = Qb3/Vb2' Solution of the above equation can give the plasma timeactivity curve of 3-0MFD in terms of the total 1 8 F time-activity curve in plasma that is usually mea sured directly. In other words, if the fractions of 3-0MFD in plasma samples are assayed at a few time points, the parameter values of kbl2, kb2, and kb3, and the time-activity curve Comfd can be deter mined by curve-fitting procedures (Huang et aI., 1991) . After the curve of Comfd(t) is determined, Cfit) can be obtained as the difference between Cn 8 and C O mfd .
In the above derivation, it is assumed that there are no other labeled metabolites in plasma. While this is valid for FDOPA studies with carbidopa pre treatment, some other labeled metabolites (Melega et aI., 1990a (Melega et aI., , 1991b appear in plasma when carbi dopa is not given. The majority of these metabolites are not expected to cross the BBB, owing to their hydrophilicity. However, they contribute to the to tal 1 8 F activity in the plasma samples. To account for this situation, the second and third compart ments of Fig. 2C can be considered as for 3-0MFD and other labeled metabolites together (i.e., total non-FDOPA component). Equation 7 and the pro cedure described above can still be used directly to give the time-activity curve of FDOPA in plasma (i.e., Cfd). In this case, a C) is added to the symbols of the rate constants to distinguish them from those for 3-0MFD alone. After the time-activity curve of FDOPA is obtained, Eq. 5 can be used to curve fit the 3-0MFD fractions to provide the time-activity curve of 3-0MFD by using estimated Cfd as the input function and considering Qb2 and Qb3 as for 3-0MFD only (i.e., excluding other labeled metab olites).
METHODS
Synthesis of FDOPA
FDOPA (specific activity 1-2 CiJmmol) was synthe sized following the procedure previously described (Lux en et ai., 1990).
PET studies
Ten drug-free volunteers (age 21.8 ± 3.9 years) deemed normal by history and physical examination were re cruited in accordance with the policies of the UCLA Hu man Subject Protection Committee. The volunteers were fasted for 4 h, and a dose of carbidopa (100 mg in four subjects; 250 mg in three; 0 mg in three) was given orally 60 min before the injection of FDOPA. Each subject was placed supine in a PET scanner (Siemens CTI 831) and a headholder was used to immobilize the head in a position to allow the whole brain to be covered by the 15 imaging planes (6.75-cm interplane separation) of the scanner. Subjects were told not to move during the study, were positioned in a comfortable posture, and were not spoken to during the study. Low ambient lighting and minimal machinery noise defined the environment. A transmission scan (using a 68Ge ring source) was performed to provide attenuation information for later attenuation correction of the emission scans.
A bolus of FDOP A (5 mCi) was injected intravenously over -30 s and a sequence of PET scans (6 x 0.5 min, 4
x 3 min, 5 x 10 min, 3 x 20 min, total time of 125 min) was started concurrently. Arterial blood samples (-1 ml each) were taken at 0.16-min intervals for 2 min, I-min intervals for another 3 min, and at gradually increased intervals until the end of the PET scan sequence. The blood samples were centrifuged and plasma taken for ra dioactivity counting in a well counter. The samples at 5, 10, 30, 60, and 120 min were also assayed biochemically by HPLC for separation of FDOPA, 3-0MFD, and other labeled metabolites (Melega et aI., 1990b (Melega et aI., , 1991 .
In five separate human studies, the arterial blood sam ples were taken in duplicate for counting in well counter for 18F activities in whole blood and in plasma. Hemat ocrits were also measured.
PET images were reconstructed with a Hann recon struction filter (cutoff frequency 1.0 x Nyquist fre quency) to give an in-plane spatial resolution of 8.4 mm full width at half-maximum and an axial resolution of 6 mm full width at half-maximum.
Regions of interest (-4-5 cm 2 in area on a cross sectional plane of largest striatal area) were defined sep arately according to the apparent boundary of the struc ture on the emission images for the left and right striata (caudate and putamen), based on a summed image from 60 to 120 min. Regions of interest (-10 cm 2 in area) for the cerebellar hemispheres were similarly drawn, but were based on early images (1-lO min). These regions of interest were then applied to the serial PET images ob tained at various scan times to give tissue 1 8F time activity curves of the corresponding regions. The curves from the left and right sides were averaged to give one striatal and one cerebellar time-activity curve for each study.
Data analysis
Plasma time-activity curves of FDOPA and 3-0MFD were obtained based on the model-fitting approach de scribed in Theory, with the total 18F time-activity curve in plasma used as the input function and the percentage 3-0MFD data from biochemical assay as the fitted mea surements.
In the studies with both whole-blood and plasma 1 8F measurements, the whole-blood time-activity curve was fitted by the following equation to estimate the partition coefficients of FDOPA and 3-0MFD in whole blood rel ative to plasma:
where Cfd(t) and Comfd(t) are, respectively, the time activity curves of FDOPA and 3-0MFD in plasma as ob tained from the model-fitting approach (Eq. 7); Het is the measured hematocrit in peripheral whole blood; and PI (1 -Het) and P2 are the partition coefficients of FDOPA and 3-0MFD in whole blood relative to the plasma con centration. The hematocrit was included in the partition coefficient because the human red blood cell membrane is not very permeable to L-DOPA (Floud and Fahn, 1981) .
The striatal time-activity curve for each study was fit ted with the striatal FDOPA model described earlier ( Fig.  2A and Eq. 2).The distribution volume of 3-0MFD in cerebral tissue was assumed to be uniform and equal to J Cereb Blood Flow Metab, Vol. I 1, No.6, 1991 1.0 (Horne et aI., 1984; Doudet et aI., 1990; Melega et aI., 1991b) . A fixed blood volume of 5% was assumed for striatal and cerebellar tissue regions (Phelps et aI., 1979) . The whole-blood radioactivity concentrations were cal culated according to the following equation that assumed a hematocrit of 40% and accounted for the separate par tition coefficients of FDOP A and 3-0MFD in blood:
where P I and P2 were the average of the estimates from the studies with both whole-blood and plasma measure ments. For studies that contained labeled metabolites other than 3-0MFD (i.e., without carbidopa), the plasma component due to these metabolites was assumed con fined to plasma (i.e., not entering the red blood cell) and was grouped together with Cfit) in the above estimation of the whole-blood radioactivity concentrations.
The convergence of the model fitting was slow with large variability for the Ks estimate. The fitting was thus performed with a constraint on the ratio of Ks to K,. A range from 0.5 to 3.0 of the constrained value was used for each striatal curve. The constrained value that gave the lowest total residual sum of squares of the 10 model fittings was used as a fixed value in other subsequent fittings. With the constraint on the distribution volume of 3-0MFD (i.e., Kslk6 = 1) and the KsIK, ratio, there re mained four variable parameters (K I, k2, k3, and k4) in the model fitting. Each striatal curve was also model fitted without k4 (i.e., by setting k4 equal to zero). The F test (Landaw and DiStefano, 1984; Bates and Watts, 1988) was used to examine if the model with k4 gave a signifi cantly better fit to the striatal tissue data.
The model fitting to the cerebellar time-activity curve was similarly performed (with the KpslKpl ratio con strained to the Ksl K I value determined from striatal curves), except the cerebellar FDOPA model (Fig. 2B ) was used. With the constraint on the distribution volume of 3-0MFD and the KpslKpl ratio, there were only two variable parameters (Kp" kp2) in the model fitting. The effect of the total scan time on the reliability of various model parameters was examined by gradually reducing the length of the tissue curves in the model fitting from 120 to 55 min.
The effects of tissue heterogeneity on the measured striatal time-activity curve and on the parameter esti mates were examined. Time-activity curves of various amounts of tissue mixture were simulated by appropri ately averaging the striatal and cerebellar time-activity curves (assuming the time-activity curve in tissue adja cent to the striatum is similar to that of the cerebellum). The range examined was from -30 to + 30% of the ad jacent tissue contribution {i.e., (simulated curve) = [Csm(t) + pCcm(t)]/[1 + p], with the P value ranging from -30 to + 30%}. The negative P values correspond to the case of having some mixture effect corrected from the PET -measured striatal curve. The simulated activity curves were then fitted by the striatal model to examine the changes in the estimated parameter values.
A software package, BLD (Carson et aI., 1981) for ki netic data modeling and simulation was used to perform all the model fittings in this study, using a weighted least squares criterion and the Marquardt algorithm. The weightings used were inversely proportional to the vari ances of the measurements that were approximated as 0.01 fCwbdt/tJ.t + (C,ItJ.t), where Ct was the measured tissue radioactivity concentration, D.l was the scan time of the measurement, and the integral was over the scan time. The first term in the variance approximation was to account for errors and uncertainties in the estimation of the vascular radioactivity due to the blood volume in tis sue. The coefficient 0.01 was chosen such that the first term was large in the early time when blood activity was high but became relatively insignificant in late times. As ymptotic values of the standard errors of the estimates were calculated from the covariance matrix of the esti mates (Landaw and DiStefano, 1984; Huang et aI., 1986 ). Figure 3 shows the time-activity curves of total 18 F in whole blood and in plasma in a typical study. Figure 4 shows the fractions of 3-0MFD in plasma as determined by chemical assay. The model fitting to these measurements is also presented. Based on this model fitting, the separated time-activity curves of FDOPA and 3-0MFD along with the total 18 F curve in plasma are shown in Fig. 5 . Table 1 summarizes the parameter values of the plasma FDOPA model (Fig. 2C) as determined by the model fittings to the chemically assayed plasma data in each subject. The partition coefficients of FDOPA and 3-0MFD in whole blood relative to plasma were found to be 1.0 1 ± 0.06 times (1 -Het) and 1.08 ± 0.07, respectively. Figure 6A shows the tissue time-activity curves obtained from serial PET images in a normal sub ject. As shown, the measured striatal and cerebellar curves were found to be fitted well, respectively, by the FDOPA models of Fig. 2A . 1 determined uniquely from a single striatal curve (i.e., the model can fit the data equally well with a wide range of K5 values). Without constraining the value of Ks, the convergence was slow, and in 3 of 10 cases, no convergence was obtained in 30 itera tions (the maximal number of iterations selected for the present study). By fixing the ratio of K5 to Kl to various values in the fitting, the total residual sum of squares over the 10 studies is plotted in Fig. 7 A and is shown to have a minimum near the value of 1.7. This value for KslKl was used in all subsequent model fits. The estimated values of the model pa rameters for each study are shown in Table 2 . Based on the model fitting, the ratios of FDA (plus its metabolites) to total tissue radioactivity in stria tum are 24 ± 7, 48 ± 9, 61 ± 6, and 67 ± 3%, respectively, at 10, 30, 60, and 120 min after FDOPA injection. These results are consistent with the biochemical data obtained in primates (Melega et ai., 1991a) . The result of fitting the tissue curves of Fig. 6A , but with the model of zero k4 ' is shown in Fig. 6B . The values of the parameter estimates for zero k4 are summarized in Table 3 as a comparison with those allowing a variable nonzero k4 . With the F test, the fitting by the model with nonzero k4 was found to be significantly better than that with zero k4 in 8 of 10 studies [i.e., F value with (1, 14) degrees of freedom was larger than the threshold value of 4.60 for p < 0.05].
RESULTS
The parameter estimates and the standard errors of the estimates are shown in Fig. 8 as a function of the total scan length. The estimates as well as their standard errors did not change significantly for total scan times longer than 90 min. Figure 7B 
Time (min) sensitivity of the parameter estimates to the Ks/K] constraint. Although the value of the individual pa rameter changes, the overall uptake constant of FDOPA with respect to the plasma FDOPA con centration [i.e., K3 = K]kAk2 + k3)] is insensitive to the exact value of the constraint used. The effect of tissue mixture on the estimated k4 value is shown in Fig. 9 . The value of k4 estimate is seen to increase for larger amount of tissue mixture, but, over the range examined, the value of k4 estimate is not af fected by >25%. The estimated value of k3 de creased for increased mixture (from 0.05/min to 0.026/min for mixture level of -10 to + 30%), The estimated values of K] and k2 were not affected over this range. However, from -10 to -30% mixture levels, the values of K1, k2' and k3 increased by 1.2, 3.9, and 2.4 times, respectively, The large changes in the k2 and k3 estimates over this range were prob- Studies 1-3 were done without carbidopa; studies 4-7 were with 100 mg of carbidopa; studies 8-10 were with 250 mg of carbidopa.
The rate constants marked with primes are for FDOPA con version to the combined pool of OMFD and other labeled me tabolites; the symbols without the prime refer to the conversion to OMFD alone. Please see legend to Fig. 2C and text for sym bols and abbreviations.
a Value was fixed in fitting.
ably due to an overcorrection of the mixture effect in the measured striatal curves.
DISCUSSION
The present results show that the model configu rations of Fig. 2 describe well the tissue and plasma kinetics of FDOPA in humans as measured with PET. With these models, the component due to 3-0MFD (a labeled metabolite not related to cere bral tissue functions) can be separated from the to tal radioactivity in tissue, with the remaining com ponent directly related to the transport and decar boxylation of FDOPA and the subsequent clearance of metabolites. From the kinetic data of an FDOPA PET study, the modeling approach is thus capable of providing information on the BBB transport, the decarboxylation, as well as the turnover rate of its metabolites in the striatum. The reliability and lim itation of this extracted information are related to a multiple of factors that need to be carefully consid ered.
Separation of plasma curves
The separation of the plasma time-activity curve into FDOPA and 3-0MFD components in the present study was based on a modeling approach with an explicit model configuration of Fig. 2C for the conversion of plasma FDOPA to 3-0MFD. Based on this model, the conversion rate constant from FDOPA to 3-0MFD (kb12) in the studies with carbidopa is comparable to that for the conversion to 3-0MFD plus other metabolites (kb12 ' ), indicating the fraction of plasma FDOPA converted in the periphery to labeled metabolites other than 3-0MFD is small, while for studies without carbi dopa, the value of kb12 ' is significantly larger than that of kb12 • The conversion rate constant to 3-0MFD alone (i.e., kb12) , however, does not cor relate with the use of carbidopa. This indicates that carbidopa does not affect the conversion of FDOPA to 3-0MFD in the periphery, consistent with the biochemical information that carbidopa is a specific inhibitor of AAAD (Melega et aI., 1990a) . There is, however, a large intersubject variability in the con version rate constant that prevents the use of a sin gle fixed value for all subjects to simplify the study procedure. Although the conversion rate constant to 3-0MFD in the periphery does not depend on the carbidopa level, the plasma FDOPA level is higher with carbidopa than without. This along with a brain uptake mechanism for FDOPA that is not af fected by carbidopa level (see discussion on BBB transport below) would give a higher striatal uptake of the tracer with carbidopa.
The model configuration of Fig. 2C may seem oversimplistic for describing the various transport/ chemical pathways and organs in the body for FDOPA and 3-0MFD, but the model can fit the biochemically assayed data well. More complicated model configurations certainly can be formulated and would be more descriptive of the multiple pro cesses involved. For the present study, however, only five plasma samples per study were assayed biochemically to give the activity percentages of FDOPA and its metabolites. The measurements will not allow us to formulate a model configuration much more complicated than the one of Fig. 2C . Extending the total study time and increasing the number of biochemical separations will improve this limitation. However, advancement in the bio chemical assay to shorten the separation procedure is needed to make this practically feasible.
To investigate the effect of having inaccuracies in the model configuration for the separation of plasma FDOPA curves, the traditional method of using an ad hoc exponential function to fit the bio chemically assayed percentage FDOPA data had also been used. Compared with those from the mod eling approach, the exponential fitting gave an arti factual peak in the early part of the separated 3-0MFD curve in some studies (due to an underes timation of the percentage FDOPA fraction at early times), and the number of exponential terms needed to fit the data varies from study to study. In terms of the estimated model parameters of FDOPA in stri atum, however, the effect was found to be ex tremely small as shown in Table 3 . The use of the
. A: Tissue time-activity curves (squares, striatum; cir cles, cerebellum) after an intra venous bolus injection of FDOPA. The solid curves are fits by models of Fig. 2A ........
Time (min) modeling approach also allows the plasma curve separation and the fitting of the tissue curves to be potentially integrated into a single estimation pro cedure.
The time-activity curve in whole blood obtained in this study does not parallel that in plasma. This is consistent with having different partition coeffi cients for whole-blood FDOPA and 3-0MFD rela tive to plasma concentrations. At early times when most plasma/blood activity is in the form of FDOPA, the radioactivity concentration ratio be tween whole blood and plasma is approximately equal to (1 -Het), This indicates that FDOPA is all in plasma and not in red blood cells. At late times (e.g., 120 min) when most plasma radioactivity is in the form of 3-0MFD, the whole blood/plasma ratio is � 1.0, suggesting that 3-0MFD permeates the red blood cell membrane. It is still unclear, however, what transport/chemical mechanisms account for their different permeability across the red blood cell membrane. This is currently under investigation in our laboratory. The difference in permeability be tween FDOPA and 3-0MFD can potentially be em ployed to separate the two labeled components in plasma, based on the measurements of whole-blood and plasma radioactivity concentrations similar to what has been used for e I C]nomifensine studies (Salmon et aI., 1990) .
Estimation of vascular 18 F activity
In this study, the whole-blood time-activity curve was not measured in every study, but was estimated according to Eq. 9 from the separated plasma FDOPA and 3-0MFD curves. Effects of errors in the blood volume component on the estimated parameters were investigated by changing the as sumed value of CRV from 0.05 to 0.08. The esti mated values of k2 and k3 were affected the most with up to 30% decreases, but with parallel changes in these two parameters, resulting in <5% change in the K3 estimate. All parameter estimates were in sensitive to changes in the partition coefficients (P I and P2) of FDOPA and 3-0MFD in blood. Also, changing the relative size of the variance compo nent in the weightings (e.g., including/excluding ra dioactivity decay correction in the variance esti mates) of the model fitting did not significantly af fect the resulted estimates of the model parameters. In fact, the parameter estimates were not found to change much even with a completely different Studies 1-3 were done without carbidopa; studies 4-7 were with 100 mg of carbidopa; studies 8-10 were with 250 mg of carbidopa.
is the decarboxylase rate constant in striatum with respect to plasma FDOPA concentration. DVs = K,/(kz + k3) denotes the distribution volume of FDOPA in striatum. DVc = Kp/kpz denotes the distribution volume of FDOPA in cerebellum.
Values in parentheses for each study are the asymptotic standard errors of the parameter estimate. See text and Fig. 2 for model parameters and abbreviations.
weighting function of zero weightings in the first 3 min and a uniform weighting afterward.
Estimation constraints
In the present study, the distribution volume of 3-0MFD in cerebral tissue was assumed to be 1.0 mllg, based on results obtained using 3-0MFD as the tracer (Doudet et aI., 1990 ) and on biochemical data (Horne et aI., 1984; Melega et aI., 1991a) . We have investigated the effects of potential errors in this assumed value in the model fitting by varying the value from 1.0 to 0.7 ml/g in O.I-ml/g steps. The estimated values of k3' K3, and DVs (distribution volume of FDOPA in striatum) were changed by +40, +20, and -20%, respectively. The estimates of K1, k2' and k4' however, were not affected. For cerebellum, changing the distribution volume of 3-0MFD from 1.0 to 0.7 mllg decreased the esti mates of both KI P and k2p (by -10 and 30%, respec tively) and resulted in an increase of the distribution volume of FDOPA in cerebellum (DVc) by -20%. Also, the use of a distribution volume of 1.0 ml/g in the fitting usually resulted in the smallest residual sum of squares.
J Cereb Blood Flow Metab, Vol. 11, No.6, 1991 Given the noise level of the tissue measurements in the present study, the value of Ks (forward BBB transport constant for plasma 3-0MFD) is uniden tifiable (in the sense of having a unique and reliable estimate) from a single striatal time-activity curve. Over the 10 striatal curves obtained in the present study, however, the total residual sum of square has its minimum around KslKI = 1.7. In other words, if all 10 curves were model fitted together with the constraint that they have the same KslKI ratio, one would obtain an estimate of 1.7. Moreover, the min imal residual sum of square of the 10 cerebellar curves also occurs around the same value for Kpsl Kpl' The use of a common ratio is based on the reasoning that the ratio represents the relative transport efficiency of 3-0MFD and FDOPA in crossing the BBB and is expected to be less affected by measurement errors, such as the partial volume effect, which are different from study to study. In the investigation of the effect of the constraint on the model parameters, the estimated parameter val ues for k2 and k3 were found to be changed in a similar way, when the constraint was varied in the range from 0.5 to 3.0. The value of K3 that repre- sents the total decarboxylation constant from plasma FDOPA as well as the KJ and k4 values, however, are not affected by the constraint (Fig.  7B) .
Recently, Reith et ai. (1990) have used a compart mental model to analyze FDOPA kinetics in rat studies. Although similar in configuration to the models examined here, their model does not ac count for the clearance of FDA and its metabolites in striatum. Also, different assumptions and con straints were used. In their model, the ratio of KJlk2 was assumed equal to K51k6 and was the same for all cerebral structures. We have tested the use of equal K/k2 and Kslk6 values in the estimation, and the effects on the parameter estimates are similar to those described earlier for using a distribution vol ume of 0.7 mllg for 3-0MFD. The constraint of hav ing the same ratio for different cerebral structures may not be valid for PET imaging studies, because of the dependency of the PET measured concentra tions on the structural size that can affect differ ently the estimates of KJ and K5 for different struc tures (Hoffman et aI., 1979; Mazziotta et aI., 1981) .
Effect of cerebral blood flow and BBB transport
Blood flow is not explicitly accounted for in the models of Fig. 2 for striatum and cerebellum, but is implicitly included in the parameters KJ and K5• The rate of FDOPA transport from arterial plasma to tissue is KJCfd according to the model of Fig. 2 , while it is F[1 -exp(-PS I F)]Cfd based on the Ren kin-Crone capillary model for the first-pass extrac tion of FDOPA in tissue, where F is blood flow and PSis the permeability-surface product of the BBB for the tracer. In other words, K 1 can be considered as a composite constant of F[1 -exp(-PS I F)]. The KI value estimated in the present study is �0.031 mllmin/g [comparable with the value of 0.037 mIl min/g recently reported for rat striatum (Reith et aI., 1990) ]. Assuming a blood flow value of 0.8 ml/min/g for the striatum, the first-pass extraction fraction is only 4% and the PS product is 0.032 mllminlg, much smaller than the nominal blood flow to the tissue. In this case, one can show, by series expansion of the exponential term, that KJ is approximately equal to PS and is thus insensitive to blood flow changes.
The permeability of FDOPA (and 3-0MFD) across the BBB is known to be mediated by the neutral amino acid carrier system in the BBB (01-dendorf, 1971 ). Since these channels are saturable (Oldendorf, 1971) , the transport of FDOPA across the BBB (i.e., the value of K1) is expected to be affected by the neutral amino acid level in plasma (Leenders et aI., 1986b) . In the present study, all the human subjects were fasted, and the plasma neutral amino acid levels were not expected to have deviated much from each other. This probably ac counts for the relatively constant KI values among the subjects studied (Table 2) . On the other hand, the subjects were given three different amounts of carbidopa before the study. The constancy of the K 1 value also suggested that carbidopa did not affect the transport of FDOPA across the BBB.
Decarboxylation rate of FDOP A in striatum
As compared to the Patlak graphical analysis that gives the uptake constant (K3) from plasma FDOPA to tissue FDA (Martin et ai., 1989) , the present modeling approach can provide the value of k3 [with a precision of about ±25% (Table 2) ] that is specific to the decarboxylation of FDOPA to FDA. Al though the absolute value of the k3 estimate is some what dependent on the estimation constraints used in the model fitting, their consistent use should al low large changes in k3 to be measured with the modeling approach. The present results show the k 1 . 3 va ue III normal subjects has an average value of 0.0411min that is comparable to that of k2• This im plies that about half of the FDOPA that normally crosses the BBB into striatum is decarboxylated while the other half is transported back out of tis� sue. This, combined with the BBB forward trans port constant K1 , gives a K3 value of 0.015 mllmin/g. 0.14 0.12
0.08 Total Scan Time (min)
The value of K3 has been measured before with Patlak analysis (Martin et aI., 1989) to be -0.8 mIl min/striatum in young adults. Assuming a unilateral striatal size of 13 ml in humans (Pasik et aI ., 1978) , their reported value is equivalent to a value of 0.06 mllmin/g, much larger than the one obtained in the present study. of L-DOPA decarboxylation is how the decarboxyl ation rate of FDOPA is related to the endogenous rate of dopamine formation. In normal dopaminer gic neurons, dopamine is formed from tyrosine through hydroxylation (by tyrosine hydroxylase to L-DOPA) and decarboxylation (by AAAD to dopa mine) reactions. It has previously been shown that tyrosine hydroxylation is the limiting reaction in this pathway and AAAD is in excess (Masserano and Weiner, 1983) . One could argue that even if the decarboxylation rate constant (k3) of FDOPA fol lowed that of L-DOPA, the k3 value alone does not necessarily give information about the rate of dopa mine formation unless the endogenous L-DOPA level is also known. Since the endogenous L-DOPA level in tissue is believed to be small and to vary depending on pathology, the decarboxylation rate obtained from FDOPA measurements may not have much direct relevance to the rate of endogenous dopamine formation. This has been a concern about the interpretation of FDOPA PET studies. If tissue AAAD is, however, in large excess, the measured value of k3 is expected to be more depen dent on the molecular diffusion and other cellular processes that transport FDOPA to the site of FDOPA decarboxylation (Hefti et ai., 1981) and not dependent on the intrinsic chemical reaction rate of decarboxylation. In other words, in this case, the decarboxylation reaction is not the real limiting step, and the value of k3 would be constant unless the amount of AAAD dropped to such a low level that the tissue L-DOPA level began saturating the enzyme and the decarboxylation reaction rate of 
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FDOPA was affected by L-DOPA competition. This limiting case is more likely to occur when the neu ronal function is immensely compromised in dis ease states as could occur in Parkinson's disease. Therefore, decrease in the k3 value could indicate changes in the rate of dopamine formation and have relevance to neuronal function. Further investiga tions, including biochemical, neurological, and ki netic studies, are, however, needed to resolve this important issue.
Turnover rate of labeled metabolites
The inclusion of a clearance pathway (k4) for the FDA and metabolites compartment in the model of Fig. 2A differs from other proposed FDOPA kinetic models (Reith et aI., 1990) . The central argument for not including k4 is that the clearance of the me tabolites from tissue would be slow and would not affect the estimates if neglected. The present re sults, however, show that ignoring k4 would signif icantly affect the estimates of other parameters, es pecially that of K3 (from 0.015 to 0.010 mllmin/g). Although the k4 value estimated in normal subjects is not very large (corresponding to a half-time of 160 min) and does not cause a large deviation from a straight line in the Patlak plot, statistical test (F test) on the model fitting in the present study indicated the tissue kinetics are more consistent with a non zero k4 than without it. Also, as shown in Table 2 and illustrated in Fig. 6 , if k4 is neglected, the esti mated distribution volume of FDOPA in striatum is larger than that in cerebellum. This is inconsistent with the fact that FDOPA is decarboxylated in stri atum but not in cerebellum, because by assuming the same BBB transport mechanism (forward and reverse) for striatum and cerebellum, one should expect the distribution volume of FDOPA in stria tum to be smaller than that in cerebellum. Allowing a nonzero k4 ' the result on the estimated distribu tion volume for striatum and cerebellum agrees well with this consideration (Table 2) .
Owing to the limited spatial resolution of the PET images and the uncertainty in defining the exact boundary of the striatum, the measured striatal time-activity curve may consist of a component that is due to the adjacent tissue that does not have spe cific uptake of FDOPA (Huang et al., 1987) . One may question whether this could have accounted for the nonzero k4 estimate in the model fitting . The investigation of the tissue mixture addressed this question. Assuming that the adjacent tissue has ki netics identical to those in cerebellum, one can re move this component from the measured striatal curve. Figure 9 shows that by correcting this con tribution from the adjacent tissue, the estimated k4 value is reduced by no more than 25%. In other words, the mixture of kinetics from adjacent tissue, although having some effect on the estimated k4 value, cannot account for the existence of the non zero k4 value. We have also applied the striatal model (with nonzero k4) to cerebellar curves. In only 2 of the 10 studies did it give reasonable curve fitting that yielded a k4 estimate of �0.025/min. In the remaining eight studies, the fitting either gave negative or extremely large parameter estimates or did not converge after 30 iterations.
As shown in the accompanying article (Melega et al., 1991a) , the concentration of FDA in primates at 60 min after FDOPA injection is much larger than those of its metabolites (mostly FHV A). This indi cates that, in normals, the metabolic rate of FDA is quite slow. Since FDA does not cross cell mem branes to any significant degree, its clearance from the tissue compartment must include FDA metabo lism to FHVA. Therefore, the k4 estimate repre sents a combination of the metabolic rate of FDA and the physical clearance rate of FHV A from tis sue, although depending on the relative magnitude of the rate constants of the two processes, the es timate may reflect primarily either process. More direct biochemical and kinetic data on FDA and its metabolites in cerebral tissue, however, are needed to understand the exact significance of k4 • Also, it remains to be determined experimentally whether pathophysiological change in the human dopamine system will be reflected in changes in the estimated value of k4 •
